{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T15:17:24Z","timestamp":1716823044047},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1,15]]},"DOI":"10.2146\/ajhp140897","type":"journal-article","created":{"date-parts":[[2015,12,31]],"date-time":"2015-12-31T11:13:21Z","timestamp":1451560401000},"page":"56-59","source":"Crossref","is-referenced-by-count":6,"title":["Elevated International Normalized Ratio values in a patient receiving warfarin and ceftaroline"],"prefix":"10.1093","volume":"73","author":[{"given":"Nada M.","family":"Farhat","sequence":"first","affiliation":[{"name":"Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, and Department of Pharmacy, Henry Ford Hospital, Detroit, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa S.","family":"Hutchinson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Henry Ford Hospital, Detroit, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Henry Ford Hospital, Detroit, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041102212702000_b1-0730056","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: anti-thrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"key\n\t\t\t\t2019041102212702000_b2-0730056","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11239-011-0555-z","article-title":"Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure","volume":"31","author":"Lee","year":"2011","journal-title":"J Thromb Thrombolysis"},{"key":"key\n\t\t\t\t2019041102212702000_b3-0730056","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"key\n\t\t\t\t2019041102212702000_b4-0730056","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.amjmed.2011.08.014","article-title":"Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults","volume":"125","author":"Baillargeon","year":"2012","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019041102212702000_b5-0730056","volume-title":"Teflaro (ceftaroline fosamil) prescribing information","year":"2013"},{"key":"key\n\t\t\t\t2019041102212702000_b6-0730056","unstructured":"European Medicines Agency. Public assessment report for Zinforo(ceftaroline fosamil) (June21, 2012). www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002252\/WC500132587.pdf (accessed 2015 Oct 19)."},{"key":"key\n\t\t\t\t2019041102212702000_b7-0730056","unstructured":"AstraZeneca UK Limited. Zinforo 600 mg powder for concentrate for solution for infusion: summary of product characteristics (October2, 2015). www.medicines.org.uk\/emc\/medicine\/26966 (accessed 2015 Oct 19)."},{"key":"key\n\t\t\t\t2019041102212702000_b8-0730056","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1345\/aph.1Q771","article-title":"Hemarthrosis in a patient on warfarin receiving ceftaroline: a case report and brief review of cephalosporin interactions with warfarin","volume":"46","author":"Bohm","year":"2012","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t2019041102212702000_b9-0730056","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/phar.1435","article-title":"High incidence of discontinuations due to adverse events in patients treated with ceftaroline","volume":"34","author":"Jain","year":"2014","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t2019041102212702000_b10-0730056","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1345\/aph.1H423","article-title":"Proposal for a new tool to evaluate drug interaction cases","volume":"41","author":"Horn","year":"2007","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t2019041102212702000_b11-0730056","first-page":"531","article-title":"Reduction of vitamin K2 concentration in human liver associated with the use of broad spectrum antimicrobials","volume":"17","author":"Conly","year":"1994","journal-title":"Clin Invest Med"},{"key":"key\n\t\t\t\t2019041102212702000_b12-0730056","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1345\/aph.1D489","article-title":"Enhanced hypoprothrombinemia with warfarin due to azithromycin","volume":"38","author":"Rao","year":"2004","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t2019041102212702000_b13-0730056","doi-asserted-by":"crossref","first-page":"45","DOI":"10.12659\/AJCR.889866","article-title":"Acute warfarin toxicity: an unanticipated consequence of amoxicillin\/clavulanate administration","volume":"15","author":"Larsen","year":"2014","journal-title":"Am J Case Rep"},{"key":"key\n\t\t\t\t2019041102212702000_b14-0730056","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2146\/ajhp070243","article-title":"Cefazolin-induced hypoprothrombinemia","volume":"65","author":"Chung","year":"2008","journal-title":"Am J Health-Syst Pharm"},{"key":"key\n\t\t\t\t2019041102212702000_b15-0730056","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1128\/AAC.29.6.1108","article-title":"Cephalosporin-induced hypoprothrombinemia: is the N-methylthiotetrazole side chain the culprit?","volume":"29","author":"Agnelli","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041102212702000_b16-0730056","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00007691-200002000-00029","article-title":"Role of P-glycoprotein in drug disposition","volume":"22","author":"Tanigawara","year":"2000","journal-title":"Ther Drug Monit"},{"key":"key\n\t\t\t\t2019041102212702000_b17-0730056","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/sj.tpj.6500220","article-title":"Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors","volume":"4","author":"Wadelius","year":"2004","journal-title":"Pharmacogenomics J"},{"key":"key\n\t\t\t\t2019041102212702000_b18-0730056","first-page":"6901","article-title":"Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells","volume":"49","author":"Gosland","year":"1989","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t2019041102212702000_b19-0730056","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1056\/NEJMcp011603","article-title":"Antibiotic-associated diarrhea","volume":"346","author":"Bartlett","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102212702000_b20-0730056","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1345\/aph.19025","article-title":"Tolterodine\u2013warfarin drug interaction","volume":"33","author":"Colucci","year":"1999","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t2019041102212702000_b21-0730056","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.279.9.657","article-title":"Acetaminophen and other risk factors for excessive warfarin anticoagulation","volume":"279","author":"Hylek","year":"1998","journal-title":"JAMA"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/73\/2\/56\/28334633\/ajhp0056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T03:01:27Z","timestamp":1567479687000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/73\/2\/56\/5101593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,15]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,1,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp140897","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,1,15]]},"published":{"date-parts":[[2016,1,15]]}}}